恒瑞医药吡咯替尼新适应症获批上市，辅助治疗乳腺癌

2022-06-02

2022年6月2日，国家药监局官网显示，恒瑞医药自主研发的马来酸吡咯替尼片新适应症获批上市，联合曲妥珠单抗及多西他赛，适用于治疗表皮生长因子受体2（HER2）阳性早期或局部晚期乳腺癌患者的新辅助治疗，为乳腺癌患者提供了一种新型的新辅助治疗方案。吡咯替尼是一款不可逆性HER2/EGFR双靶点的酪氨酸激酶抑制剂。（动脉网）

市场大事

宏观大事，市场动态

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":617836403,"tweetId":"617836403","gmtCreate":1654161846806,"gmtModify":1704859009271,"author":{"id":4091686409339050,"authorId":4091686409339050,"authorIdStr":"4091686409339050","name":"硬科技","avatar":"https://static.tigerbbs.com/5af5a3bfa4ca7d0599601f1fbecf0d30","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"starInvestorFlag":false},"themes":[{"themeId":"309c7f94260944df9570069109a44aae","categoryId":"bc7f9e79615545918dda2e7d7cfb9e15","name":"市场大事","type":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/detail&rndata={\"themeId\":309c7f94260944df9570069109a44aae}&rnconfig={\"headerBarHidden\": true}","description":"宏观大事，市场动态","image":"https://static.tigerbbs.com/9eaf0bfce8dcfc7bf515f26e2cfe3f9e"}],"images":[],"coverImages":[],"title":"恒瑞医药吡咯替尼新适应症获批上市，辅助治疗乳腺癌","extraTitle":"","html":"<html><head></head><body><p>2022年6月2日，国家药监局官网显示，恒瑞医药自主研发的马来酸吡咯替尼片新适应症获批上市，联合曲妥珠单抗及多西他赛，适用于治疗表皮生长因子受体2（HER2）阳性早期或局部晚期乳腺癌患者的新辅助治疗，为乳腺癌患者提供了一种新型的新辅助治疗方案。吡咯替尼是一款不可逆性HER2/EGFR双靶点的酪氨酸激酶抑制剂。（动脉网）</p></body></html>","htmlText":"<html><head></head><body><p>2022年6月2日，国家药监局官网显示，恒瑞医药自主研发的马来酸吡咯替尼片新适应症获批上市，联合曲妥珠单抗及多西他赛，适用于治疗表皮生长因子受体2（HER2）阳性早期或局部晚期乳腺癌患者的新辅助治疗，为乳腺癌患者提供了一种新型的新辅助治疗方案。吡咯替尼是一款不可逆性HER2/EGFR双靶点的酪氨酸激酶抑制剂。（动脉网）</p></body></html>","text":"2022年6月2日，国家药监局官网显示，恒瑞医药自主研发的马来酸吡咯替尼片新适应症获批上市，联合曲妥珠单抗及多西他赛，适用于治疗表皮生长因子受体2（HER2）阳性早期或局部晚期乳腺癌患者的新辅助治疗，为乳腺癌患者提供了一种新型的新辅助治疗方案。吡咯替尼是一款不可逆性HER2/EGFR双靶点的酪氨酸激酶抑制剂。（动脉网）","highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/617836403","repostId":0,"isVote":1,"tweetType":1,"viewCount":1430,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["600276"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":289,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/617836403"}